Dave Mott, president and chief executive officer of AstraZeneca’s biologics business unit, MedImmune, has decided to leave the company at the end of July for personal reasons. Tony Zook, chief executive officer of AstraZeneca’s North American business and executive vice president of global marketing, has been appointed head of MedImmune on an interim basis until a permanent successor is named.
   
David Brennan, chief executive officer of AstraZeneca, said, “Under Dave Mott’s leadership, the team at MedImmune has built a unique capability to discover, develop and deliver innovative biologic treatments — an important element of AstraZeneca’s future strategy. We will continue to build on that strong platform, maximizing the potential of products in the MedImmune portfolio while delivering innovative new biological medicines and vaccines that treat and prevent disease.”